553 related articles for article (PubMed ID: 16385351)
21. [Biologic therapy with anti-TNFα in spondyloarthritides and other autoimmune diseases].
Lapadula G
Reumatismo; 2005; 57(4 Suppl):22-9. PubMed ID: 16385352
[TBL] [Abstract][Full Text] [Related]
22. Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis.
Eder L; Thavaneswaran A; Chandran V; Gladman DD
Ann Rheum Dis; 2014 Jun; 73(6):1007-11. PubMed ID: 23619157
[TBL] [Abstract][Full Text] [Related]
23. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
Zhang J; Xie F; Delzell E; Yun H; Lewis JD; Haynes K; Chen L; Beukelman T; Saag KG; Curtis JR
Arthritis Care Res (Hoboken); 2015 May; 67(5):624-32. PubMed ID: 25370912
[TBL] [Abstract][Full Text] [Related]
24. Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging.
Hirose W; Nishikawa K; Hirose M; Nanki T; Sugimoto H
Mod Rheumatol; 2009; 19(1):20-6. PubMed ID: 18762862
[TBL] [Abstract][Full Text] [Related]
25. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis.
van der Heijde D; Klareskog L; Landewé R; Bruyn GA; Cantagrel A; Durez P; Herrero-Beaumont G; Molad Y; Codreanu C; Valentini G; Zahora R; Pedersen R; MacPeek D; Wajdula J; Fatenejad S
Arthritis Rheum; 2007 Dec; 56(12):3928-39. PubMed ID: 18050208
[TBL] [Abstract][Full Text] [Related]
26. [Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis. Italian Rheumatology Society].
Salvarani C; Olivieri I; Cantini F; Marchesoni A; Punzi L; Scarpa R; Matucci-Cerinic M
Reumatismo; 2004; 56(3):133-4, 136-8. PubMed ID: 15470517
[No Abstract] [Full Text] [Related]
27. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.
Hjeltnes G; Hollan I; Førre O; Wiik A; Lyberg T; Mikkelsen K; Agewall S
Clin Exp Rheumatol; 2013; 31(3):415-21. PubMed ID: 23465067
[TBL] [Abstract][Full Text] [Related]
28. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.
Nixon R; Bansback N; Brennan A
Rheumatology (Oxford); 2007 Jul; 46(7):1140-7. PubMed ID: 17478472
[TBL] [Abstract][Full Text] [Related]
29. Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis.
Yazici Y; Yazici H
Clin Exp Rheumatol; 2008; 26(3):449-52. PubMed ID: 18578967
[TBL] [Abstract][Full Text] [Related]
30. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.
Klareskog L; van der Heijde D; de Jager JP; Gough A; Kalden J; Malaise M; Martín Mola E; Pavelka K; Sany J; Settas L; Wajdula J; Pedersen R; Fatenejad S; Sanda M;
Lancet; 2004 Feb; 363(9410):675-81. PubMed ID: 15001324
[TBL] [Abstract][Full Text] [Related]
32. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
Tijhuis GJ; van de Putte LB; Breedveld FC
Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
[TBL] [Abstract][Full Text] [Related]
34. [New drugs and treatment strategies for rheumatoid arthritis].
Fantini F
Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
[TBL] [Abstract][Full Text] [Related]
35. Comparison between adalimumab, etanercept, and infliximab in rheumatoid arthritis: comment on the article by Hetland et al.
Francis S; Block MJ
Arthritis Rheum; 2010 Sep; 62(9):2826; author reply 2826-8. PubMed ID: 20556822
[No Abstract] [Full Text] [Related]
36. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody.
Baker DE
Rev Gastroenterol Disord; 2004; 4(4):196-210. PubMed ID: 15580154
[TBL] [Abstract][Full Text] [Related]
37. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.
Kristensen LE; Christensen R; Bliddal H; Geborek P; Danneskiold-Samsøe B; Saxne T
Scand J Rheumatol; 2007; 36(6):411-7. PubMed ID: 18092260
[TBL] [Abstract][Full Text] [Related]
38. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
39. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.
Asahina A; Ishii N; Tohma S
J Dermatol; 2012 Feb; 39(2):199-201. PubMed ID: 21463364
[No Abstract] [Full Text] [Related]
40. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
Soini EJ; Hallinen TA; Puolakka K; Vihervaara V; Kauppi MJ
J Med Econ; 2012; 15(2):340-51. PubMed ID: 22168785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
